Evidence-based clinical practice guideline: Inhaled nitric oxide for neonates with acute hypoxic respiratory failure

Respiratory Care

Volumn 55, Issue 12, 2010, Pages 1717-1745

  DiBlasi, Robert M ^a   Myers, Timothy R ^b   Hess, Dean R ^c  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hypoxemia; Inhaled nitric oxide; Mechanical ventilation; Neonate; Persistent pulmonary hypertension of the newborn

Indexed keywords

METHEMOGLOBIN; NITRIC OXIDE; NITROGEN DIOXIDE; PLACEBO;

ACUTE HYPOXIC RESPIRATORY FAILURE; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; EXTRACORPOREAL OXYGENATION; HIGH FREQUENCY VENTILATION; HUMAN; LOW DRUG DOSE; LUNG INJURY; METHEMOGLOBINEMIA; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; OXYGEN SATURATION; PATIENT MONITORING; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY FAILURE; REVIEW; VENTILATOR;

ADMINISTRATION, INHALATION; ANOXIA; BRONCHODILATOR AGENTS; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY INSUFFICIENCY;

EID: 78650413714     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Frostell C, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 1993;78(3):427-435.
2. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83(6):2038-2047. Erratum in: Circulation 1991;84(5):2212.
3. Bin-Nun A, Schreiber MD. Role of INO in the modulation of pulmonary vascular resistance. J Perinatol 2008;(Suppl 3):S84-S92.
4. Restrepo RD. AARC clinical practice guidelines: from "referencebased to evidence-based" (editorial). Respir Care 2010;55(6): 787-788.
5. Finer N, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006;(4): CD000399. DOI: 10.1002/14651858.CD000399.pub2.
6. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000;342(7):469-474.
7. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336(9):597-604.
8. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336(9):605-610.
9. Mercier JC, Lacaze T, Storme L, Rozé JC, Dinh-Xuan AT, Dehan M. Disease-related response to inhaled nitric oxide in newborns with severe hypoxaemic respiratory failure. French Paediatric Study Group of Inhaled NO. Eur J Pediatr 1998;157(9):747-752.
10. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998;01(3 Pt 1):325-334.
11. Day RW, Allen EM, Witte MK. A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure. Chest 1997; 112(5):1324-1331.
12. Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR, Kourembanas S. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1997;100(5):E7.
13. Cornfield DN, Maynard RC, deRegnier RA, Guiang SF 3rd, Barbato JE, Milla CE. Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Pediatrics 1999;104(5 Pt 1):1089-1094.
14. Barefield ES, Karle VA, Phillips JB 3rd, Carlo WA. Inhaled nitric oxide in term infants with hypoxemic respiratory failure. J Pediatr 1996;129(2):279-286.
15. Christou H, Van Marter LJ, Wessel DL, Allred EN, Kane JW, Thompson JE, et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med 2000;28(11): 3722-3727.
16. González A, Fabres J, D'Apremont I, Urcelay G, Avaca M, Gandolfi C, Kattan J. Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. J Perinatol 2010;30(6):420-424.
17. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997;99(6):838-845.
18. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997;131(1 Pt 1):55-62.
19. The Franco-Belgian Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet 1999;354(9184):1066-1071.
20. Finer NN, Sun JW, Rich W, Knodel E, Barrington KJ. Randomized, prospective study of low-dose versus high-dose inhaled nitric oxide in the neonate with hypoxic respiratory failure. Pediatrics 2001;108(4):949-955.
21. Sadiq HF, Mantych G, Benawra RS, Devaskar UP, Hocker JR. Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. J Perinatol 2003;23(2):98-103.
22. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, et al; Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 2004;113(3 Pt 1):559-564.
23. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340(8823):818-819.
24. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340(8823):819-820.
25. Kinsella JP, Abman SH. Inhalational nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatrics 1993; 91(5):997-998.
26. Kinsella JP, Abman SH. Efficacy of inhalational nitric oxide therapy in the clinical management of persistent pulmonary hypertension of the newborn. Chest 1994;105(3 Suppl):92S-94S.
27. Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994;124(2):302-308.
28. Buhrer C, Merker G, Falke K, Versmold H, Obladen M. Doseresponse to inhaled nitric oxide in acute hypoxemic respiratory failure of newborn infants: a preliminary report. Pediatr Pulmonol 1995;19(5):291-298.
29. Turbow R, Waffarn F, Yang L, Sills J, Hallman M. Variable oxygenation response to inhaled nitric oxide in severe persistent pulmonary hypertension of the newborn. Acta Paediatr 1995;84(11): 1305-1308.
30. Muller W, Kachel W, Lasch P, Varnholt V, Konig SA. Inhaled nitric oxide for avoidance of extracorporeal membrane oxygenation in the treatment of severe persistent pulmonary hypertension of the newborn. Intensive Care Med 1996;22(1):71-76.
31. Stranak Z, Zabrodsky V, Simak J. Changes in alveolar-arterial oxygen difference and oxygenation index during low-dose nitric oxide inhalation in 15 newborns with severe respiratory insufficiency. Eur J Pediatr 1996;155(10):907-910.
32. Demirakça S, Dötsch J, Knothe C, Magsaam J, Reiter HL, Bauer J, Kuehl PG. Inhaled nitric oxide in neonatal and pediatric acute respiratory distress syndrome: dose response, prolonged inhalation, and weaning. Crit Care Med 1996;24(11):1913-1919.
33. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996;98(4 Pt 1): 706-713.
34. Lönnqvist PA. Inhaled nitric oxide in newborn and paediatric patients with pulmonary hypertension and moderate to severe impaired oxygenation: effects of doses of 3-100 parts per million. Intensive Care Med 1997;23(7):773-779.
35. Hoffman GM, Ross GA, Day SE, Rice TB, Nelin LD. Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn. Crit Care Med 1997;25(2):352-359.
36. Laubscher B, Greenough A, Kavvadia V, Devane SP. Response to nitric oxide in term and preterm infants. Eur J Pediatr 1997;156(8): 639-642.
37. Biban P, Trevisanuto D, Pettenazzo A, Ferrarese P, Baraldi E, Zacchello F. Inhaled nitric oxide in hypoxaemic newborns who are candidates for extracorporeal life support. Eur Respir J 1998;11(2): 371-376.
38. Mok Q, Yates R, Tasker RC. Persistent pulmonary hypertension of the term neonate: a strategy for management. Eur J Pediatr 1999; 158(10):825-827.
39. Lönnqvist PA. Efficacy and economy of inhaled nitric oxide in neonates accepted for extra-corporeal membrane oxygenation. Acta Physiol Scand 1999;167(2):175-179.
40. Kossel H, Bauer K, Kewitz G, Karaca S, Versmold H. Do we need new indications for ECMO in neonates pretreated with high-frequency ventilation and/or inhaled nitric oxide? Intensive Care Med 2000;26(10):1489-1495.
41. Tworetzky W, Bristow J, Moore P, Brook MM, Segal MR, Brasch RC, et al. Inhaled nitric oxide in neonates with persistent pulmonary hypertension. Lancet 2001;357(9250):118-120.
42. Gupta A, Rastogi S, Sahni R, Bhutada A, Bateman D, Rastogi D, et al. Inhaled nitric oxide and gentle ventilation in the treatment of pulmonary hypertension of the newborn: a single-center, 5-year experience. J Perinatol 2002;22(6):435-441.
43. Hwang SJ, Lee KH, Hwang JH, Choi CW, Shim JW, Chang YS, Park WS. Factors affecting the response to inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn infants. Yonsei Med J 2004;45(1):49-55.
44. Guthrie SO, Walsh WF, Auten K, Clark RH. Initial dosing of inhaled nitric oxide in infants with hypoxic respiratory failure. J Perinatol 2004;24(5):290-294.
45. Fakioglu H, Totapally BR, Torbati D, Raszynski A, Sussmane JB, Wolfsdorf J. Hypoxic respiratory failure in term newborns: clinical indicators for inhaled nitric oxide and extracorporeal membrane oxygenation therapy. J Crit Care 2005;20(3):288-293.
46. Cannon BC, Feltes TF, Fraley JK, Grifka RG, Riddle EM, Kovalchin. Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. Pediatr Cardiol 2005;26(5):565-569.
47. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88(5 Pt 1):2128-2138.
48. Bando K, Turrentine MW, Sharp TG, Sekine Y, Aufiero TX, Sun K, et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 1996;112(6):1600-1607.
49. Journois D, Pouard P, Mauriat P, Malhere T, Vouhe P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994;107(4):1129-1135.
50. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000;356(9240):1464-1469.
51. Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev 2005; (4):CD005055. DOI: 10.1002/14651858.CD005055.pub2.
52. Rosenberg AA, Kennaugh JM, Moreland SG, Fashaw LM Hale KA, Torielli FM, et al. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension. J Pediatr 1997;131(1 Pt 1):70-75.
53. Dobyns EL, Griebel J, Kinsella JP, Abman SH, Accurso FJ. Infant lung function after inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 1999;28(1): 24-30.
54. Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J Pediatr 2002;140(3):306-310.
55. Clark RH, Huckaby JL, Kueser TJ, Walker MW, Southgate WM, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol 2003;23(4):300-303.
56. Ichiba H, Matsunami S, Itoh F, Ueda T, Ohsasa Y, Yamano T. Three-year follow-up of term and near-term infants treated with inhaled nitric oxide. Pediatr Int 2003;45(3):290-293.
57. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 2000;136(5):611-617.
58. Ellington M, O'Reilly D, Allred EN, McCormick MC, Wessel DL, Kourembanas S. Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 2001;107(6):1351-1356.
59. Konduri GG, Vohr B, Robertson C, Sokol GM, Solimano A, Singer J, et al. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. Neonatal Inhaled Nitric Oxide Study Group. J Pediatr 2007;150(3):235-240.
60. Truog WE, Castor CA, Sheffield MJ. Neonatal nitric oxide use: predictors of response and financial implications. J Perinatol 2003; 23(2):128-132.
61. Jacobs P, Finer NN, Robertson CM, Etches P, Hall EM, Saunders LD. A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: results from a Canadian randomized clinical trial. Crit Care Med 2000;28(3):872-878.
62. Jacobs P, Finer NN, Fassbender K, Hall E, Robertson CM. Costeffectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: eighteen- to 24-month follow-up for Canadian patients. Crit Care Med 2002;30(10):2330-2334.
63. Lorch SA, Cnaan A, Barnhart K. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114(2):417-426.
64. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003;112(6 Pt 1):1351-1360.
65. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 131(1 Pt 1):55-62, 1997.
66. Kinsella JP, Abman SH. High-frequency oscillatory ventilation augments the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Nitric Oxide Study Group. Chest 1998;114(1 Suppl):100S.
67. Aly H, Sahni R, Wung JT. Weaning strategy with inhaled nitric oxide treatment in persistent pulmonary hypertension of the newborn. Arch Dis Child Fetal Neonatal Ed 1997;76(2):F118-F122.
68. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346(8966):51-52.
69. Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996;153(6 Pt 1):1985-1987.
70. Francoise M, Gouyon JB, Mercier JC. Hemodynamics and oxygenation changes induced by the discontinuation of low-dose inhalational nitric oxide in newborn infants. Intensive Care Med 1996; 22(5):477-481.
71. Christenson J, Lavoie A, O'Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000;161(5):1443-1449.
72. Sokol GM, Fineberg NS, Wright LL, Ehrenkranz RA. Changes in arterial oxygen tension when weaning neonates from inhaled nitric oxide. Pediatr Pulmonol 2001;32(1):14-19.
73. Carriedo H, Rhine W. Withdrawal of inhaled nitric oxide from nonresponders after short exposure. J Perinatol 2003;23(7):556-558.
74. Behrends M, Beiderlinden M, Peters J. Combination of sildenafil and bosentan for nitric oxide withdrawal. Eur J Anaesthesiol 2005; 22(2):155-157.
75. Keller RL, Hamrick SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004;5(2):184-187.
76. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91(1):307-310.
77. Buysse C, Fonteyne C, Dessy H, De Laet MH, Biarent D. The use of dipyridamole to wean from inhaled nitric oxide in congenital diaphragmatic hernia. J Pediatr Surg 2001;36(12):1864-1865.
78. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998;115(4):875-882.
79. Saiki Y, Nitta Y, Tsuru Y, Tabayashi K. Successful weaning from inhaled nitric oxide using dipyridamole. Eur J Cardiothorac Surg 2003;24(5):837-839.
80. Fernandez R, Artigas A, Blanch L. Ventilatory factors affecting inhaled nitric oxide concentrations during continuous-flow administration. J Crit Care 1996;11(3):138-143.
81. Hudome SM, Ergenekon EN, Darrow KA, Richard RB, Snider MT, Marks KH. Precise control of nitric oxide concentration in the inspired gas of continuous flow respiratory devices. Pediatr Pulmonol 1996;22(3):182-187.
82. Yamaguchi N, Togari H, Suzuki S. During neonatal mechanical ventilatory support, the delivered nitric oxide concentration is affected by the ventilatory setting. Crit Care Med 2000;28(5):1607-1611.
83. Betit P. Nitric oxide administration during pediatric mechanical ventilation. Respir Care Clin N Am 1996;2(4):587-605.
84. Skimming JW, Stephan PJ, Blanch PB, Banner MJ. Propagation of nitric oxide pools during controlled mechanical ventilation. J Clin Monit Comput 1998;14(3):157-164.
85. Skimming JW, Blanch PB, Banner MJ. Behavior of nitric oxide infused at constant flow rates directly into a breathing circuit during controlled mechanical ventilation. Crit Care Med 1997;25(8):1410-1416.
86. Foubert L, Mareels K, Fredholm M, Lundin S, Stenqvist O. A study of mixing conditions during nitric oxide administration using simultaneous fast response chemiluminescence and capnography. Br J Anaesth 1997;78(4):436-438.
87. Tibballs J, Hochmann M, Carter B, Osborne A. An appraisal of techniques for administration of gaseous nitric oxide. Anaesth Intensive Care 1993;21(6):844-847.
88. Hess D, Ritz R, Branson RD. Delivery systems for inhaled nitric oxide. Respir Care Clin N Am 1997;3(3):371-410.
89. Young JD, Roberts M, Gale LB. Laboratory evaluation of the INOvent nitric oxide delivery device. Br J Anaesth 1997;79(3):398-401.
90. Kirmse M, Hess D, Fujino Y, Kacmarek RM, Hurford WE. Delivery of inhaled nitric oxide using the Ohmeda INOvent Delivery System. Chest 1998;113(6):1650-1657.
91. Sydow M, Bristow F, Zinserling J, Allen SJ. Flow-proportional administration of nitric oxide with a new delivery system: inspiratory nitric oxide concentration fluctuation during different flow conditions. Chest 1997;112(2):496-504.
92. Center for Devices and Radiological Health. Guidance for industry and for FDA reviewers: guidance document for premarket notification submissions for nitric oxide delivery apparatus, nitric oxide analyzer and nitrogen dioxide analyzer. Issued January 24, 2000. Updated September 8, 2010. http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm073763.htm. Accessed October 11, 2010.
93. Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med 1994;149(5):1327-1334.
94. Dreyfuss D, Saumon G. Barotrauma is volutrauma but which volume is the one responsible? Intensive Care Med 1992;18(3):139-141.
95. Ricard JD, Dreyfuss D, Saumon G. Ventilator-induced lung injury. Eur Respir J 2003;22(Suppl 42):2S-9S.
96. de Waal K, Evans N, van der Lee J, van Kaam A. Effect of lung recruitment on pulmonary, systemic, and ductal blood flow in preterm infants. J Pediatr 2009;154(5):651-655.
97. Hiesmayr MJ, Neugebauer T, Lassnigg A, Steltzer H, Haider W, Gilly H. Performance of proportional and continuous nitric oxide delivery systems during pressure- and volume-controlled ventilation. Br J Anaesth 1998;81(4):544-552.
98. Betit P, Adatia I, Benjamin P, Thompson JE, Wessel DL. Inhaled nitric oxide evaluation of a continuous titration delivery technique for infant mechanical ventilation and manual ventilation. Respir Care 1995;40(7):706-715.
99. Ceccarelli P, Bigatello LM, Hess D, Kwo J, Melendez L, Hurford WE. Inhaled nitric oxide delivery by anesthesia machines. Anesth Analg 2000;90(2):482-488.
100. Hoehn T, Krause M, Hentschel R. High-frequency oscillatory ventilation augments the response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Eur Respir J 1998;11(1): 234-238.
101. Coates EW, Klinepeter ME, O'Shea TM. Neonatal pulmonary hypertension treated with inhaled nitric oxide and high-frequency ventilation. J Perinatol 2008;28(10):675-679.
102. Fujino Y, Kacmarek RM, Hess DR. Nitric oxide delivery during high-frequency oscillatory ventilation. Respir Care 2000;45(9): 1097-1104.
103. Mortimer TW, Math MC, Fajardo CA. Inhaled nitric oxide delivery with high-frequency jet ventilation: a bench study. Respir Care 1996;41(10):895-902.
104. Platt DR, Swanton D, Blackney D. Inhaled nitric oxide (INO) delivery with high-frequency jet ventilation (HFJV). J Perinatol 2003; 23(5):387-391.
105. 2 during combined treatment of infants with nasal CPAP and NO. Intensive Care Med 2006;32(12):2034-2041.
106. Lindwall R, Frostell CG, Lönnqvist PA. Delivery characteristics of a combined nitric oxide nasal continuous positive airway pressure system. Paediatr Anaesth 2002;12(6):530-536.
107. Trevisanuto D, Doglioni N, Micaglio M, Zanardo V. Feasibility of nitric oxide administration by neonatal helmet-CPAP: a bench study. Paediatr Anaesth 2007;17(9):851-855.
108. Doglioni N, Micaglio M, Zanardo V, Trevisanuto D. Long-term use of neonatal helmet-CPAP: a case report. Minerva Anestesiol 2009; 75(12):750-753.
109. Ivy DD, Wiggins JW, Badesch DB, Kinsella JP, Kelminson LL, Abman SH. Nitric oxide and prostacyclin treatment of an infant with primary pulmonary hypertension. Am J Cardiol 1994;74(4): 414-416.
110. Kinsella JP, Parker TA, Ivy DD, Abman SH. Noninvasive delivery of inhaled nitric oxide therapy for late pulmonary hypertension in newborn infants with congenital diaphragmatic hernia. J Pediatr 2003;142(4):397-401.
111. Ambalavanan N, El-Ferzli GT, Roane C, Johnson R, Carlo WA. Nitric oxide administration using an oxygen hood: a pilot trial. PLoS One 2009;4(2):e4312.
112. Hess D, Bigatello L, Hurford WE. Toxicity and complications of inhaled nitric oxide. Respir Care Clin N Am 1997;3(4):487-503.
113. Crow JP, Beckman JS. The role of peroxynitrite in nitric oxidemediated toxicity. Curr Topics Microbiol Immunol 1995;196:57-73.
114. Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994;94:2407-2413.
115. Hallman M, Bry K, Lappalainen U. A mechanism of nitric oxideinduced surfactant dysfunction. J Appl Physiol 1996;80(6):2035-2043.
116. Hallman M, Waffarn F, Bry K, Turbow R, Kleinman MT, Mautz WJ, et al. Surfactant dysfunction after inhalation of nitric oxide. J Appl Physiol 1996;80(6):2026-2034.
117. Van Meurs KP, Cohen TL, Yang G, Somaschini M, Kuruma P, Dennery PA. Inhaled NO and markers of oxidant injury in infants with respiratory failure. J Perinatol 2005;25(7):463-469.
118. Hallman M, Bry K, Turbow R, Waffarn F, Lappalainen U. Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure. J Pediatr 1998;132(5):827-829.
119. Stephens RJ, Freeman G, Evans MJ. Early response of lungs to low levels of nitrogen dioxide. Light and electron microscopy. Arch Environ Health 1972;24(3):160-179.
120. Evans MJ, Stephens RJ, Cabral LJ, Freeman G. Cell renewal in the lungs of rats exposed to low levels of NO2. Arch Environ Health 1972;24(3):180-188.
121. Rasmussen TR, Kjaergaard SK, Tarp U, Pedersen OF. Delayed effects of NO2 exposure on alveolar permeability and glutathione peroxidase in healthy humans. Am Rev Respir Dis 1992;146(3): 654-599.
122. Bylin G, Lindvall T, Rehn T, Sundin B. Effects of short-term exposure to ambient nitrogen dioxide concentrations on human bronchial reactivity and lung function. Eur J Respir Dis 1985;66(3):205-217.
123. Westfelt UN, Lundin S, Stenqvist O. Safety aspects of delivery and monitoring of nitric oxide during mechanical ventilation. Acta Anaesthesiol Scand 1996;40(3):302-310.
124. Breuer J, Waidelich F, Irtel von Brenndorff C, Sieverding L, Rosendahl W, Baden W, et al. Technical considerations for inhaled nitric oxide therapy: time response to nitric oxide dosing changes and formation of nitrogen dioxide. Eur J Pediatr 1997;156(6): 460-462.
125. Beghetti M, Sparling C, Cox PN, Stephens D, Adatia I. Inhaled NO inhibits platelet aggregation and elevates plasma but not intraplatelet cGMP in healthy human volunteers. Am J Physiol Heart Circ Physiol 2003;285(2):H637-H642.
126. George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 1998;132(4):731-734.
127. United States Department of Labor, Occupational Safety and Health Administration. Nitric oxide in workplace atmospheres (ID190). Updated April 7, 2010. http://www.osha.gov/dts/sltc/methods/inorganic/id190/id190.html. Accessed October 11, 2010.
128. United States Department of Labor. Occupational Safety and Health Administration. Nitrogen dioxide in workplace atmospheres (ion chromatography) (ID182). Updated March 17, 2010. http://www.osha.gov/dts/sltc/methods/inorganic/id182/id182.html. Accessed October 11, 2010.
129. Phillips ML, Hall TA, Sekar K, Tomey JL. Assessment of medical personnel exposure to nitrogen oxides during inhaled nitric oxide treatment of neonatal and pediatric patients. Pediatrics 1999;104(5 Pt 1):1095-1100.
130. Dhillon JS, Kronick JB, Singh NC, Johnson CC. A portable nitric oxide scavenging system designed for use on neonatal transport. Crit Care Med 1996;24(6):1068-1071.
131. Kinsella JP, Griebel J, Schmidt JM, Abman SH. Use of inhaled nitric oxide during interhospital transport of newborns with hypoxemic respiratory failure. Pediatrics 2002;109(1):158-161.